Mycophenolate mofetil Teva


mycophenolate mofetil

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Mycophenolate mofetil Teva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Mycophenolate mofetil Teva.

This EPAR was last updated on 03/02/2021

Authorisation details

Product details
Mycophenolate mofetil Teva
Agency product number
Active substance
mycophenolate mofetil
International non-proprietary name (INN) or common name
mycophenolate mofetil
Therapeutic area (MeSH)
Graft Rejection
Anatomical therapeutic chemical (ATC) code

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Teva Pharma B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Computerweg 10
NL-3542 DR Utrecht
The Netherlands

Product information

22/12/2020 Mycophenolate mofetil Teva - EMEA/H/C/000882 - IA/0041


  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group


Therapeutic indication

Mycophenolate mofetil Teva is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.

Assessment history

How useful was this page?

Add your rating